Gremont Tablet contains Levocetirizine 5mg and Montelukast 10mg, a combination medication used primarily for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine is a potent, selective, third-generation antihistamine that competitively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast is a leukotriene receptor antagonist that blocks leukotriene D4 at the cysteinyl leukotriene receptor, reducing inflammation, bronchoconstriction, and mucus production associated with allergic responses. The synergistic action of these two agents provides comprehensive relief from allergic symptoms by targeting multiple pathways involved in the allergic cascade. Gremont Tablet is indicated for patients who require both antihistaminic and anti-inflammatory effects to control moderate to severe allergic manifestations. It is well-tolerated, with a favorable safety profile when used as directed. Common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. It is contraindicated in patients with known hypersensitivity to either component. Caution is advised in patients with hepatic or renal impairment. Gremont Tablet should be taken orally, once daily, preferably in the evening, or as prescribed by a healthcare professional. Regular monitoring and adherence to prescribed dosage ensure optimal therapeutic outcomes.